SlideShare ist ein Scribd-Unternehmen logo
1 von 35
1

ABDELFATTAH AL ZAQQA
SCHOOL OF COMPUTER SCIENCE
PRINCESS SUMAYA UNIVERSITY FOR TECHNOLOGY

Abdelfattah Al Zaqqa, PSUT-Amman-Jordan

Data Mining
Methodologies for
Pharmacovigilance
Agenda


Introduction



Examples



Some facts of ADRs and drugs.



Pharmacovigilance



Phv methodologies



Data mining



Computational methodology-Pre-Marketing



Computational methodology-Post Marketing



Future perspectives

Abdelfattah Al Zaqqa, PSUT-Amman-Jordan

2
Introduction



Medicines: is the applied science or
practice of the diagnosis, treatment, and
prevention of disease.



Most medicines have both good and bad
effects.



Bad effects called Adverse Drug Reactions
(ADRs) , it differs from side effects.



Side effects whether therapeutic or
adverse

3

Abdelfattah Al Zaqqa, PSUT-Amman-Jordan

ADRs cause over 700,000
emergency department visits
each year in the United States
Example of ADRs and side effects
• Desired and undesired effects of an aspirin therapy
reduce your headache or
fever
reduce the ability of your
blood to clot

× bleeding of intestine

Abdelfattah Al Zaqqa, PSUT-Amman-Jordan

4
5

Facts
New drug may takes 10 years and
billions of dollars.



Drug interactions may also increase
the risk of ADRs

ADRs may cause over 100,000
deaths among hospitalized
patients each year.



ADRs is the fourth largest cause of
death in US
136 $ billion annual cost in US from
ADRs.

ADRs may led to withdrawals drug.









Abdelfattah Al Zaqqa, PSUT-Amman-Jordan
6

Pharmacovigilance (PhV)


Pharmacovigilance (PhV) is the science that
concerns with the
detection, assessment, understanding and
prevention of ADRs



Pharmacovigilance (PhV)=drug safety
surveillance



Surveillance for premarketing (i.e. Data from
preclinical & clinical trials) and post-marketing
(i.e. throughout a drug’s market life)

Abdelfattah Al Zaqqa, PSUT-Amman-Jordan



Phv trend to link the Preclinical
human safety with information
from post marketing.
Phv methodologies



7

Phv historically relied on biological
experiments or manual review of case
report
In vitro Safety Pharmacology
Profiling (SPP) is one of the
fundamental method for preclinical;
by testing compounds with
biochemical and cellular assays.
SPP still not efficient (cost and time)

Abdelfattah Al Zaqqa, PSUT-Amman-Jordan
Computational methodologies for PhV



Vast quantities and complexity of
data to be analyzed



Computational methods at both premarketing and post-marketing stages
are more efficient in time and cost (i.e.
can accurately detect ADRs in a
timely fashion)



SPP still not efficient (cost and time)

Abdelfattah Al Zaqqa, PSUT-Amman-Jordan

8



Datasets are available



EMA and NCA are example of
specialized companies that maintain
and develop database of ADRs
What is Data mining ?!


Data mining  the process of extracting previously unknown, valid and
actionable information from large information sources or databases



So what we will need to do this process?!


project goals: detection and prevention of ADRs



dataset acquisition: Available



data cleaning and preprocessing: organize the raw data obtained



data mining: extract useful information



data interpretation: Analysis of data



utilization: the act of using

Abdelfattah Al Zaqqa, PSUT-Amman-Jordan

9
Computational methodology-Pre-Marketing



Most of existing research devoted to develop computational methods.



These research can be categorized into
I.

protein target-based.

II.

chemical structure-based approaches.

III.

integrative approach.

Abdelfattah Al Zaqqa, PSUT-Amman-Jordan

10
Computational methodology-Pre-Marketing-Protein
target-based



Drugs typically work by activating or inhibiting the function of
a protein, which in turn results in therapeutic benefits to a
patient.



drugs with similar in vitro protein binding profiles tend to similar
side-effects, Fliri et al.



Fukuzaki et al, proposed a method to predict ADRs using subpathways “cooperative pathways” (pathways that function
together).



They developed an algorithm called CoopeRativE Pathway
Enumerator (CREPE) to select combinations of sub-pathways



it depends on the availability of gene-expression data
observed under identical conditions.

Abdelfattah Al Zaqqa, PSUT-Amman-Jordan

11
CoopeRativE Pathway Enumerator
(CREPE)

V vertex, I itemset (activation conditions)
Abdelfattah Al Zaqqa, PSUT-Amman-Jordan

12
Computational methodology-PreMarketing-Protein target-based


More recently, Brouwers et al proposed that the side
effect similarity of drugs could be attributed to their target
proteins being close in a molecular network.



They proposed a pathway neighborhood measure to
assess the closest distance of drug pairs according to their
target proteins in the human protein protein interaction
network and found network neighborhoods to only
account for 5.8% of the side-effect similarities compared
to 64% by shared drug targets.

Abdelfattah Al Zaqqa, PSUT-Amman-Jordan

13
Computational methodology-PreMarketing-Protein target-based


Pouliot et al. applied logistic regression (LR) models.



To identify potential ADRs manifesting in 19 specific
system organ classes (SOCs), as defined by the Medical
Dictionary for Regulatory Activities ,across 485
compounds in 508 BioAssays in the PubChem database.



The models were evaluated using leave-one-out-crossvalidation. The mean AUCs (area under the receiver
operating characteristic curve) ranged from 0.60 to 0.92
across different SOCs.

Abdelfattah Al Zaqqa, PSUT-Amman-Jordan

14
Chemical Structure-based Approachpremarketing


It attempts to link ADRs to their chemical structure.



Bender et al, explore the correlation but the positive predictive was quit
low under 0.5. but at least he proved the concept.



Hammann et al, employed decision tree to determine the
chemical, physical, and structural properties of compounds that
predispose them to causing ADRs



Hammann focused on ADRs in centerla nervous system (CNS),liver, and
kidney.



Hammann decision tree model positive predictive accuracies ranging
from 78.9% to 90.2%.

Abdelfattah Al Zaqqa, PSUT-Amman-Jordan

15
Chemical Structure-based Approachpremarketing


Pauwels et al. developed a sparse canonical correlation analysis (SCCA)
method to predict high-dimensional side-effect profiles of drug molecules
based on the chemical structures.



They predict 1385 side effects in the SIDER DB from chemical structures of
888 approved drugs.



16

Pauwels et al best resulting AUC(area under curve) was between 0.6088
and 0.8932
• SCCA examines the
relationships of many
variables of different
types simultaneously

Abdelfattah Al Zaqqa, PSUT-Amman-Jordan
Integrative Approach- premarketing


Huang et al. proposed a new computational framework to predict ADRs
by integrating systems biology data that include protein targets, proteinprotein interaction network, gene ontology (GO) annotation ,and
reported side effects. They predict heart-related ADRs (i.e. cardio
toxicity), which resulted in the highest AUC of 0.771.



Recently, Liu et al. investigated the use of phenotypic
information, together with chemical and biological properties of drugs, to
predict ADRs. using five machine learning algorithms: LR, Naïve Bayes
(NB), KNearest Neighbor (KNN), Random Forest (RF), and SVM.

Abdelfattah Al Zaqqa, PSUT-Amman-Jordan

17
Integrative Approach


integration of chemical, biological, and phenotypic properties
outperforms the chemical structured-based method (from 0.9054 to 0.9524
with SVM) and has the potential to detect clinically important ADRs at
both preclinical and post-market phases for drug surveillance.

Abdelfattah Al Zaqqa, PSUT-Amman-Jordan

18
Post Marketing



many ADRs may still be missed
because the clinical trials are often
small, short, and biased by excluding
patients with comorbid diseases.



do not mirror actual clinical use
situations for diverse populations




(e.g. inpatient)
thus it is important to continue the
surveillance postmarket.

Abdelfattah Al Zaqqa, PSUT-Amman-Jordan

19
Computational methodology-Post
marketing-Data sources


Spontaneous reporting systems (SRSs) is the
core data-collection system for postmarketing drug surveillance since 1960. US
FDA and the VigiBase maintain such as these
report.



World Health Organization (WHO) manage
these SRSs.

Abdelfattah Al Zaqqa, PSUT-Amman-Jordan

20
Post marketing-Spontaneous Reports



Disproportionality Analysis (DPA) involves frequency analyses of 2x2
contingency tables to quantify the degree to which a drug and ADR cooccurs “disproportionally” compared with what would be expected if
there were no association
ADR

No ADR

Total

Drug

a

b

N=a+b

No Drug

c

d

c+d

Total

M=a+c

B+d

T=a+b+c+d

Abdelfattah Al Zaqqa, PSUT-Amman-Jordan

21
Post marketing-Spontaneous Reports


Many approaches are applied the straightforward method is the
calculation of frequentist metrics
Association Measures

Definition

Relative Reporting Ratio (RRR)

(t * a) / (m * n)

Proportional Reporting Ratio (PRR)

(a * (t – n)) / (c * n)

Reporting Odds Ratio (ROR)

(a * d) / (c * b)

•

Definitions of the frequentist measures of association

Abdelfattah Al Zaqqa, PSUT-Amman-Jordan

22
Post marketing-Spontaneous Reports



Other algorithms were also developed but they are more complex, such
as gamma-Poisson shrinker (GPS) and the multi-item gamma-Poisson
shrinker (MGPS)



DPA methods are effective in detecting single Drug-ADR associations

Abdelfattah Al Zaqqa, PSUT-Amman-Jordan

23
Data Mining Algorithms



DPA methods are effective in detecting single Drug-ADR associations



Data mining for multi-item ADR associations.



Harpaz et al identified 1167 multi-item ADR associations Using a set of
162,744 reports submitted to the FDA in 2008, 67% were validated by a
domain expert



Tatonetti et al applied the bi clustering algorithm to identify drug groups
that share a common set of ADRs in SRS data.



They discovered ADRs between drugs that couldn’t be discovered using
DPA method.(e.g pravastatin and paroxetine had effect on blood
glucose)

Abdelfattah Al Zaqqa, PSUT-Amman-Jordan

24
Post marketing -Electronic Medical
Records


Electronic Medical Records :is a computerized medical record created in
an organization that delivers care, EMRs contain not only detailed patient
information but also copious longitudinal clinical data.



EMR databases consist of data in two types formats:
(1) structured (e.g., laboratory data)


Several groups have employed computational methods on

structured or coded data in EMRs to identify specific ADR signals
(2) unstructured (narrative clinical notes).

Abdelfattah Al Zaqqa, PSUT-Amman-Jordan

25
Structured & unstructured

Abdelfattah Al Zaqqa, PSUT-Amman-Jordan

26
Post marketing -Electronic Medical
Records-structured data


Yoon et al, demonstrated laboratory abnormality to be a valuable source
for PhV by examining the odds ratio of laboratory abnormalities between a
drug-exposed and a matched unexposed group using 10 years of EMR
data.



Evaluation of their algorithm on 470 randomly selected drug-andabnormal-lab-event pairs produced a positive predictive value of 0.837
and negative predictive value of 0.659.

Abdelfattah Al Zaqqa, PSUT-Amman-Jordan

27
Post marketing -Electronic Medical
Records-Unstructured Data


natural language processing (NLP) technique is required to extract the
needed information from unstructured data.



Wang et al first employed NLP techniques to extract drug-ADR



Link

Abdelfattah Al Zaqqa, PSUT-Amman-Jordan

28
Non-conventional Data Sources-Post
marketing
1.

Biomedical Literature



Shetty and Dalal retrieved articles (published between
1949 and2009), for prioritizing drug-ADR associations.



DPA was applied to identify statistically significant pairs
from the thousands of pairs in the remaining articles.



Evaluation showed that the method identified true
associations with 0.41 and 0.71 inprecision and
recall, respectively.

Abdelfattah Al Zaqqa, PSUT-Amman-Jordan

29
Non-conventional Data Sources
2. Health Forums


Data posted by users on health-related
websites may also contain valuable drug
safety information



mine drug-and-ADR from health –related
websites (e.g. DailyStrength
(http://www.dailystrength.org/))



System evaluation was conducted on a
manually annotated set of 3600 user
posts corresponding to 6 drugs. The
system was shown to achieve 0.78 in
precision and 0.70 in recall.

Abdelfattah Al Zaqqa, PSUT-Amman-Jordan

30
Non-conventional Data Sources



Chee et al, aggregated individuals’
opinions and review of drugs and used
NLP technique to group drugs.



Some drugs were withdrawn from
based on these messages.

Abdelfattah Al Zaqqa, PSUT-Amman-Jordan

31
32

Future perspectives





This presentation provides a general
overview of the current computational
methodologies applied for PhV. basic
concepts and highlight some
representative work
it is desirable to incorporate various
data sources into one framework to
understand ADRs.

Abdelfattah Al Zaqqa, PSUT-Amman-Jordan



Data mining algorithms are applicable
and useful to detect drugs
interactions.



EMR for ADR prediction is not readily
accessible for data mining, more
sophisticated studies and NLP
techniques is needed.



cause-and-effect relationships is an
intrinsically hard problem in data
mining and need to be further
investigated for the PhV application.
Useful links



https://www.mediguard.org



http://www.jmedicalcasereports.com



http://wwwstat.stanford.edu/~tibs/Correlate/



http://www.iom.edu/



http://www.smartlogic.com/



http://blogs.sas.com/content/jmp/201
2/06/04/disproportionality-analysis-iscoming-in-jmp-clinical-4-0/

Abdelfattah Al Zaqqa, PSUT-Amman-Jordan

33
References


Oxford English Dictionary definition of "medicine“



Source: The Importance of Pharmacovigilance, WHO 2002



Budnitz, D.S., Pollock, D.A., Weidenbach, K.N.,Mendelsohn, A.B., Schroeder, T.J.
and Annest, J.L. National surveillance of emergency department visits for
outpatient adverse drug events. JAMA, 296, 15 (Oct 18 2006), 1858-1866.



Hopkins, A.L. Network pharmacology: the next paradigm in drug discovery.
Nat Chem Biol, 4, 11 (Nov 2008), 682-690.



Helma C, Gottmann E, Kramer S. Knowledge discovery and data mining in
toxicology. Stat Meth Med Res. 2000;9:329–58.



http://articles.mercola.com/sites/articles/archive/2012/02/11/leading-causesof-death-cost-for-us-economy.aspx



Mutsumi Fukuzaki, Mio Seki,Side Effect Prediction using Cooperative Pathways

Abdelfattah Al Zaqqa, PSUT-Amman-Jordan

34
Thank you!

Abdelfattah Al Zaqqa, PSUT-Amman-Jordan

35

Weitere ähnliche Inhalte

Was ist angesagt?

Drug Distribution system & Hospital formulary
Drug Distribution system & Hospital formulary Drug Distribution system & Hospital formulary
Drug Distribution system & Hospital formulary Dr Manish Pal Singh
 
Detection and monitoring of ADRs
Detection and monitoring of ADRsDetection and monitoring of ADRs
Detection and monitoring of ADRsDr. Ramesh Bhandari
 
Therapeutic Drug Monitoring
Therapeutic Drug MonitoringTherapeutic Drug Monitoring
Therapeutic Drug Monitoringsunayanamali
 
Generic drugs product development
Generic drugs product developmentGeneric drugs product development
Generic drugs product developmentSachin G
 
Defined daily dose-DDD
Defined daily dose-DDDDefined daily dose-DDD
Defined daily dose-DDDMubasheeraMg
 
Regulatory terminologies used in PV (Pharmacovigilance)
Regulatory terminologies used in PV (Pharmacovigilance)Regulatory terminologies used in PV (Pharmacovigilance)
Regulatory terminologies used in PV (Pharmacovigilance)MubasheeraMg
 
Granularity of tt pro.
Granularity of tt pro.Granularity of tt pro.
Granularity of tt pro.GaneshDevane
 
Establishment of Pharmacovigilance Programme
Establishment of Pharmacovigilance ProgrammeEstablishment of Pharmacovigilance Programme
Establishment of Pharmacovigilance ProgrammeNipun Gupta
 
Investigational new drug application
Investigational new drug application Investigational new drug application
Investigational new drug application Kirsha K S
 
Patients medication history interview
Patients medication history interviewPatients medication history interview
Patients medication history interviewSubhash Yende
 
Multi component analysis (uv visible spectroscopy) by mr. pradeep swarnkar)
Multi component analysis (uv visible spectroscopy) by mr. pradeep swarnkar)Multi component analysis (uv visible spectroscopy) by mr. pradeep swarnkar)
Multi component analysis (uv visible spectroscopy) by mr. pradeep swarnkar)Pradeep Swarnkar
 
WHO International Drug Monitoring Program
WHO International Drug Monitoring ProgramWHO International Drug Monitoring Program
WHO International Drug Monitoring ProgramSnehaKhandale1
 
Pharmacy and Therapeutic Committee
Pharmacy and Therapeutic CommitteePharmacy and Therapeutic Committee
Pharmacy and Therapeutic CommitteeSubhash Yende
 
Clinical Trial Management Systems
Clinical Trial Management SystemsClinical Trial Management Systems
Clinical Trial Management SystemsDeepak Yadav
 
Education and training program in the hospital.
Education and training program in the hospital.Education and training program in the hospital.
Education and training program in the hospital.Shivaji University
 
ROLE OF PHARMACOVIGILANCE AGAINST ADVERSE DRUG REACTION
ROLE OF PHARMACOVIGILANCE AGAINST ADVERSE DRUG REACTIONROLE OF PHARMACOVIGILANCE AGAINST ADVERSE DRUG REACTION
ROLE OF PHARMACOVIGILANCE AGAINST ADVERSE DRUG REACTIONAnindya Banerjee
 

Was ist angesagt? (20)

Drug Distribution system & Hospital formulary
Drug Distribution system & Hospital formulary Drug Distribution system & Hospital formulary
Drug Distribution system & Hospital formulary
 
Detection and monitoring of ADRs
Detection and monitoring of ADRsDetection and monitoring of ADRs
Detection and monitoring of ADRs
 
Information services
Information servicesInformation services
Information services
 
Therapeutic Drug Monitoring
Therapeutic Drug MonitoringTherapeutic Drug Monitoring
Therapeutic Drug Monitoring
 
Generic drugs product development
Generic drugs product developmentGeneric drugs product development
Generic drugs product development
 
Drug information services
Drug information servicesDrug information services
Drug information services
 
Defined daily dose-DDD
Defined daily dose-DDDDefined daily dose-DDD
Defined daily dose-DDD
 
Regulatory terminologies used in PV (Pharmacovigilance)
Regulatory terminologies used in PV (Pharmacovigilance)Regulatory terminologies used in PV (Pharmacovigilance)
Regulatory terminologies used in PV (Pharmacovigilance)
 
Pharmacovigilance methods
Pharmacovigilance methodsPharmacovigilance methods
Pharmacovigilance methods
 
Granularity of tt pro.
Granularity of tt pro.Granularity of tt pro.
Granularity of tt pro.
 
Establishment of Pharmacovigilance Programme
Establishment of Pharmacovigilance ProgrammeEstablishment of Pharmacovigilance Programme
Establishment of Pharmacovigilance Programme
 
Investigational new drug application
Investigational new drug application Investigational new drug application
Investigational new drug application
 
Patients medication history interview
Patients medication history interviewPatients medication history interview
Patients medication history interview
 
Multi component analysis (uv visible spectroscopy) by mr. pradeep swarnkar)
Multi component analysis (uv visible spectroscopy) by mr. pradeep swarnkar)Multi component analysis (uv visible spectroscopy) by mr. pradeep swarnkar)
Multi component analysis (uv visible spectroscopy) by mr. pradeep swarnkar)
 
WHO International Drug Monitoring Program
WHO International Drug Monitoring ProgramWHO International Drug Monitoring Program
WHO International Drug Monitoring Program
 
Pharmacy and Therapeutic Committee
Pharmacy and Therapeutic CommitteePharmacy and Therapeutic Committee
Pharmacy and Therapeutic Committee
 
Clinical Trial Management Systems
Clinical Trial Management SystemsClinical Trial Management Systems
Clinical Trial Management Systems
 
J. SUBRAHMANYAM
J. SUBRAHMANYAMJ. SUBRAHMANYAM
J. SUBRAHMANYAM
 
Education and training program in the hospital.
Education and training program in the hospital.Education and training program in the hospital.
Education and training program in the hospital.
 
ROLE OF PHARMACOVIGILANCE AGAINST ADVERSE DRUG REACTION
ROLE OF PHARMACOVIGILANCE AGAINST ADVERSE DRUG REACTIONROLE OF PHARMACOVIGILANCE AGAINST ADVERSE DRUG REACTION
ROLE OF PHARMACOVIGILANCE AGAINST ADVERSE DRUG REACTION
 

Ähnlich wie Data mining methodologies for pharmacovigilance

Good Pharmacovigilance Practices
Good Pharmacovigilance Practices Good Pharmacovigilance Practices
Good Pharmacovigilance Practices sopi_1234
 
Advanced Methodologies in Pharmacovigilance
Advanced Methodologies in PharmacovigilanceAdvanced Methodologies in Pharmacovigilance
Advanced Methodologies in Pharmacovigilanceijtsrd
 
Signal Detection in Pharmacovigilance: Methods and Algorithms
Signal Detection in Pharmacovigilance: Methods and AlgorithmsSignal Detection in Pharmacovigilance: Methods and Algorithms
Signal Detection in Pharmacovigilance: Methods and AlgorithmsClinosolIndia
 
Indian j pharmacol b chakraborty_pv
Indian j pharmacol b chakraborty_pvIndian j pharmacol b chakraborty_pv
Indian j pharmacol b chakraborty_pvBhaswat Chakraborty
 
Data Mining and Big Data Analytics in Pharma
Data Mining and Big Data Analytics in Pharma Data Mining and Big Data Analytics in Pharma
Data Mining and Big Data Analytics in Pharma Ankur Khanna
 
A method for mining infrequent causal associations and its application in fin...
A method for mining infrequent causal associations and its application in fin...A method for mining infrequent causal associations and its application in fin...
A method for mining infrequent causal associations and its application in fin...JPINFOTECH JAYAPRAKASH
 
Challenges In Pharmacovigilance Dr Vishwas, by Dr. Vishwas Sovani MD ,VP P...
Challenges In Pharmacovigilance   Dr Vishwas, by Dr. Vishwas Sovani  MD ,VP P...Challenges In Pharmacovigilance   Dr Vishwas, by Dr. Vishwas Sovani  MD ,VP P...
Challenges In Pharmacovigilance Dr Vishwas, by Dr. Vishwas Sovani MD ,VP P...Until ROI
 
Pharmacoepidemiology
PharmacoepidemiologyPharmacoepidemiology
PharmacoepidemiologyDivjyot Kaur
 
Pharmacoepidemiology
PharmacoepidemiologyPharmacoepidemiology
PharmacoepidemiologyDivjyot Kaur
 
IRJET - E-Health Chain and Anticipation of Future Disease
IRJET - E-Health Chain and Anticipation of Future DiseaseIRJET - E-Health Chain and Anticipation of Future Disease
IRJET - E-Health Chain and Anticipation of Future DiseaseIRJET Journal
 
A method for mining infrequent causal associations and its application in fin...
A method for mining infrequent causal associations and its application in fin...A method for mining infrequent causal associations and its application in fin...
A method for mining infrequent causal associations and its application in fin...IEEEFINALYEARPROJECTS
 
System for Recommending Drugs Based on Machine Learning Sentiment Analysis of...
System for Recommending Drugs Based on Machine Learning Sentiment Analysis of...System for Recommending Drugs Based on Machine Learning Sentiment Analysis of...
System for Recommending Drugs Based on Machine Learning Sentiment Analysis of...IRJET Journal
 
Data Mining & Signal Detection In Pv
Data Mining & Signal Detection In PvData Mining & Signal Detection In Pv
Data Mining & Signal Detection In PvUntil ROI
 
Data mining in pharmacovigilance
Data mining in pharmacovigilanceData mining in pharmacovigilance
Data mining in pharmacovigilanceBhaswat Chakraborty
 
METHODS OF CAUSALITY ASSESMENT.@ Clinical Pharmacy 4th Pharm D
METHODS OF CAUSALITY ASSESMENT.@ Clinical Pharmacy 4th Pharm DMETHODS OF CAUSALITY ASSESMENT.@ Clinical Pharmacy 4th Pharm D
METHODS OF CAUSALITY ASSESMENT.@ Clinical Pharmacy 4th Pharm DDrpradeepthi
 
Pharmacovigilance organisation
Pharmacovigilance organisationPharmacovigilance organisation
Pharmacovigilance organisationSomya Solanki
 
New drug + Pharmacogenetics F22 TMSUc.pptx
New drug + Pharmacogenetics F22 TMSUc.pptxNew drug + Pharmacogenetics F22 TMSUc.pptx
New drug + Pharmacogenetics F22 TMSUc.pptxDrNabanitKumarJha1
 

Ähnlich wie Data mining methodologies for pharmacovigilance (20)

GOOD PHARMACOVIGILANCE PRACTICES
GOOD PHARMACOVIGILANCE PRACTICESGOOD PHARMACOVIGILANCE PRACTICES
GOOD PHARMACOVIGILANCE PRACTICES
 
Good Pharmacovigilance Practices
Good Pharmacovigilance Practices Good Pharmacovigilance Practices
Good Pharmacovigilance Practices
 
Advanced Methodologies in Pharmacovigilance
Advanced Methodologies in PharmacovigilanceAdvanced Methodologies in Pharmacovigilance
Advanced Methodologies in Pharmacovigilance
 
Signal Detection in Pharmacovigilance: Methods and Algorithms
Signal Detection in Pharmacovigilance: Methods and AlgorithmsSignal Detection in Pharmacovigilance: Methods and Algorithms
Signal Detection in Pharmacovigilance: Methods and Algorithms
 
Indian j pharmacol b chakraborty_pv
Indian j pharmacol b chakraborty_pvIndian j pharmacol b chakraborty_pv
Indian j pharmacol b chakraborty_pv
 
Data Mining and Big Data Analytics in Pharma
Data Mining and Big Data Analytics in Pharma Data Mining and Big Data Analytics in Pharma
Data Mining and Big Data Analytics in Pharma
 
A method for mining infrequent causal associations and its application in fin...
A method for mining infrequent causal associations and its application in fin...A method for mining infrequent causal associations and its application in fin...
A method for mining infrequent causal associations and its application in fin...
 
Challenges In Pharmacovigilance Dr Vishwas, by Dr. Vishwas Sovani MD ,VP P...
Challenges In Pharmacovigilance   Dr Vishwas, by Dr. Vishwas Sovani  MD ,VP P...Challenges In Pharmacovigilance   Dr Vishwas, by Dr. Vishwas Sovani  MD ,VP P...
Challenges In Pharmacovigilance Dr Vishwas, by Dr. Vishwas Sovani MD ,VP P...
 
Artificial intelligence
Artificial intelligenceArtificial intelligence
Artificial intelligence
 
Pharmacoepidemiology
PharmacoepidemiologyPharmacoepidemiology
Pharmacoepidemiology
 
Pharmacoepidemiology
PharmacoepidemiologyPharmacoepidemiology
Pharmacoepidemiology
 
IRJET - E-Health Chain and Anticipation of Future Disease
IRJET - E-Health Chain and Anticipation of Future DiseaseIRJET - E-Health Chain and Anticipation of Future Disease
IRJET - E-Health Chain and Anticipation of Future Disease
 
A method for mining infrequent causal associations and its application in fin...
A method for mining infrequent causal associations and its application in fin...A method for mining infrequent causal associations and its application in fin...
A method for mining infrequent causal associations and its application in fin...
 
System for Recommending Drugs Based on Machine Learning Sentiment Analysis of...
System for Recommending Drugs Based on Machine Learning Sentiment Analysis of...System for Recommending Drugs Based on Machine Learning Sentiment Analysis of...
System for Recommending Drugs Based on Machine Learning Sentiment Analysis of...
 
Data Mining & Signal Detection In Pv
Data Mining & Signal Detection In PvData Mining & Signal Detection In Pv
Data Mining & Signal Detection In Pv
 
Data mining in pharmacovigilance
Data mining in pharmacovigilanceData mining in pharmacovigilance
Data mining in pharmacovigilance
 
Bioinformatics and Drug Discovery
Bioinformatics and Drug DiscoveryBioinformatics and Drug Discovery
Bioinformatics and Drug Discovery
 
METHODS OF CAUSALITY ASSESMENT.@ Clinical Pharmacy 4th Pharm D
METHODS OF CAUSALITY ASSESMENT.@ Clinical Pharmacy 4th Pharm DMETHODS OF CAUSALITY ASSESMENT.@ Clinical Pharmacy 4th Pharm D
METHODS OF CAUSALITY ASSESMENT.@ Clinical Pharmacy 4th Pharm D
 
Pharmacovigilance organisation
Pharmacovigilance organisationPharmacovigilance organisation
Pharmacovigilance organisation
 
New drug + Pharmacogenetics F22 TMSUc.pptx
New drug + Pharmacogenetics F22 TMSUc.pptxNew drug + Pharmacogenetics F22 TMSUc.pptx
New drug + Pharmacogenetics F22 TMSUc.pptx
 

Kürzlich hochgeladen

Application orientated numerical on hev.ppt
Application orientated numerical on hev.pptApplication orientated numerical on hev.ppt
Application orientated numerical on hev.pptRamjanShidvankar
 
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...Nguyen Thanh Tu Collection
 
Fostering Friendships - Enhancing Social Bonds in the Classroom
Fostering Friendships - Enhancing Social Bonds  in the ClassroomFostering Friendships - Enhancing Social Bonds  in the Classroom
Fostering Friendships - Enhancing Social Bonds in the ClassroomPooky Knightsmith
 
NO1 Top Black Magic Specialist In Lahore Black magic In Pakistan Kala Ilam Ex...
NO1 Top Black Magic Specialist In Lahore Black magic In Pakistan Kala Ilam Ex...NO1 Top Black Magic Specialist In Lahore Black magic In Pakistan Kala Ilam Ex...
NO1 Top Black Magic Specialist In Lahore Black magic In Pakistan Kala Ilam Ex...Amil baba
 
Key note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdfKey note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdfAdmir Softic
 
Towards a code of practice for AI in AT.pptx
Towards a code of practice for AI in AT.pptxTowards a code of practice for AI in AT.pptx
Towards a code of practice for AI in AT.pptxJisc
 
FSB Advising Checklist - Orientation 2024
FSB Advising Checklist - Orientation 2024FSB Advising Checklist - Orientation 2024
FSB Advising Checklist - Orientation 2024Elizabeth Walsh
 
Unit 3 Emotional Intelligence and Spiritual Intelligence.pdf
Unit 3 Emotional Intelligence and Spiritual Intelligence.pdfUnit 3 Emotional Intelligence and Spiritual Intelligence.pdf
Unit 3 Emotional Intelligence and Spiritual Intelligence.pdfDr Vijay Vishwakarma
 
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptx
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptxHMCS Max Bernays Pre-Deployment Brief (May 2024).pptx
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptxEsquimalt MFRC
 
HMCS Vancouver Pre-Deployment Brief - May 2024 (Web Version).pptx
HMCS Vancouver Pre-Deployment Brief - May 2024 (Web Version).pptxHMCS Vancouver Pre-Deployment Brief - May 2024 (Web Version).pptx
HMCS Vancouver Pre-Deployment Brief - May 2024 (Web Version).pptxmarlenawright1
 
How to setup Pycharm environment for Odoo 17.pptx
How to setup Pycharm environment for Odoo 17.pptxHow to setup Pycharm environment for Odoo 17.pptx
How to setup Pycharm environment for Odoo 17.pptxCeline George
 
Holdier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdfHoldier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdfagholdier
 
How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17Celine George
 
Kodo Millet PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...
Kodo Millet  PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...Kodo Millet  PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...
Kodo Millet PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...pradhanghanshyam7136
 
This PowerPoint helps students to consider the concept of infinity.
This PowerPoint helps students to consider the concept of infinity.This PowerPoint helps students to consider the concept of infinity.
This PowerPoint helps students to consider the concept of infinity.christianmathematics
 
How to Create and Manage Wizard in Odoo 17
How to Create and Manage Wizard in Odoo 17How to Create and Manage Wizard in Odoo 17
How to Create and Manage Wizard in Odoo 17Celine George
 
Wellbeing inclusion and digital dystopias.pptx
Wellbeing inclusion and digital dystopias.pptxWellbeing inclusion and digital dystopias.pptx
Wellbeing inclusion and digital dystopias.pptxJisc
 
Jamworks pilot and AI at Jisc (20/03/2024)
Jamworks pilot and AI at Jisc (20/03/2024)Jamworks pilot and AI at Jisc (20/03/2024)
Jamworks pilot and AI at Jisc (20/03/2024)Jisc
 
SOC 101 Demonstration of Learning Presentation
SOC 101 Demonstration of Learning PresentationSOC 101 Demonstration of Learning Presentation
SOC 101 Demonstration of Learning Presentationcamerronhm
 

Kürzlich hochgeladen (20)

Application orientated numerical on hev.ppt
Application orientated numerical on hev.pptApplication orientated numerical on hev.ppt
Application orientated numerical on hev.ppt
 
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
 
Fostering Friendships - Enhancing Social Bonds in the Classroom
Fostering Friendships - Enhancing Social Bonds  in the ClassroomFostering Friendships - Enhancing Social Bonds  in the Classroom
Fostering Friendships - Enhancing Social Bonds in the Classroom
 
NO1 Top Black Magic Specialist In Lahore Black magic In Pakistan Kala Ilam Ex...
NO1 Top Black Magic Specialist In Lahore Black magic In Pakistan Kala Ilam Ex...NO1 Top Black Magic Specialist In Lahore Black magic In Pakistan Kala Ilam Ex...
NO1 Top Black Magic Specialist In Lahore Black magic In Pakistan Kala Ilam Ex...
 
Key note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdfKey note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdf
 
Towards a code of practice for AI in AT.pptx
Towards a code of practice for AI in AT.pptxTowards a code of practice for AI in AT.pptx
Towards a code of practice for AI in AT.pptx
 
FSB Advising Checklist - Orientation 2024
FSB Advising Checklist - Orientation 2024FSB Advising Checklist - Orientation 2024
FSB Advising Checklist - Orientation 2024
 
Unit 3 Emotional Intelligence and Spiritual Intelligence.pdf
Unit 3 Emotional Intelligence and Spiritual Intelligence.pdfUnit 3 Emotional Intelligence and Spiritual Intelligence.pdf
Unit 3 Emotional Intelligence and Spiritual Intelligence.pdf
 
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptx
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptxHMCS Max Bernays Pre-Deployment Brief (May 2024).pptx
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptx
 
HMCS Vancouver Pre-Deployment Brief - May 2024 (Web Version).pptx
HMCS Vancouver Pre-Deployment Brief - May 2024 (Web Version).pptxHMCS Vancouver Pre-Deployment Brief - May 2024 (Web Version).pptx
HMCS Vancouver Pre-Deployment Brief - May 2024 (Web Version).pptx
 
How to setup Pycharm environment for Odoo 17.pptx
How to setup Pycharm environment for Odoo 17.pptxHow to setup Pycharm environment for Odoo 17.pptx
How to setup Pycharm environment for Odoo 17.pptx
 
Holdier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdfHoldier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdf
 
How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17
 
Kodo Millet PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...
Kodo Millet  PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...Kodo Millet  PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...
Kodo Millet PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...
 
This PowerPoint helps students to consider the concept of infinity.
This PowerPoint helps students to consider the concept of infinity.This PowerPoint helps students to consider the concept of infinity.
This PowerPoint helps students to consider the concept of infinity.
 
Mehran University Newsletter Vol-X, Issue-I, 2024
Mehran University Newsletter Vol-X, Issue-I, 2024Mehran University Newsletter Vol-X, Issue-I, 2024
Mehran University Newsletter Vol-X, Issue-I, 2024
 
How to Create and Manage Wizard in Odoo 17
How to Create and Manage Wizard in Odoo 17How to Create and Manage Wizard in Odoo 17
How to Create and Manage Wizard in Odoo 17
 
Wellbeing inclusion and digital dystopias.pptx
Wellbeing inclusion and digital dystopias.pptxWellbeing inclusion and digital dystopias.pptx
Wellbeing inclusion and digital dystopias.pptx
 
Jamworks pilot and AI at Jisc (20/03/2024)
Jamworks pilot and AI at Jisc (20/03/2024)Jamworks pilot and AI at Jisc (20/03/2024)
Jamworks pilot and AI at Jisc (20/03/2024)
 
SOC 101 Demonstration of Learning Presentation
SOC 101 Demonstration of Learning PresentationSOC 101 Demonstration of Learning Presentation
SOC 101 Demonstration of Learning Presentation
 

Data mining methodologies for pharmacovigilance

  • 1. 1 ABDELFATTAH AL ZAQQA SCHOOL OF COMPUTER SCIENCE PRINCESS SUMAYA UNIVERSITY FOR TECHNOLOGY Abdelfattah Al Zaqqa, PSUT-Amman-Jordan Data Mining Methodologies for Pharmacovigilance
  • 2. Agenda  Introduction  Examples  Some facts of ADRs and drugs.  Pharmacovigilance  Phv methodologies  Data mining  Computational methodology-Pre-Marketing  Computational methodology-Post Marketing  Future perspectives Abdelfattah Al Zaqqa, PSUT-Amman-Jordan 2
  • 3. Introduction  Medicines: is the applied science or practice of the diagnosis, treatment, and prevention of disease.  Most medicines have both good and bad effects.  Bad effects called Adverse Drug Reactions (ADRs) , it differs from side effects.  Side effects whether therapeutic or adverse 3 Abdelfattah Al Zaqqa, PSUT-Amman-Jordan ADRs cause over 700,000 emergency department visits each year in the United States
  • 4. Example of ADRs and side effects • Desired and undesired effects of an aspirin therapy reduce your headache or fever reduce the ability of your blood to clot × bleeding of intestine Abdelfattah Al Zaqqa, PSUT-Amman-Jordan 4
  • 5. 5 Facts New drug may takes 10 years and billions of dollars.  Drug interactions may also increase the risk of ADRs ADRs may cause over 100,000 deaths among hospitalized patients each year.  ADRs is the fourth largest cause of death in US 136 $ billion annual cost in US from ADRs. ADRs may led to withdrawals drug.     Abdelfattah Al Zaqqa, PSUT-Amman-Jordan
  • 6. 6 Pharmacovigilance (PhV)  Pharmacovigilance (PhV) is the science that concerns with the detection, assessment, understanding and prevention of ADRs  Pharmacovigilance (PhV)=drug safety surveillance  Surveillance for premarketing (i.e. Data from preclinical & clinical trials) and post-marketing (i.e. throughout a drug’s market life) Abdelfattah Al Zaqqa, PSUT-Amman-Jordan  Phv trend to link the Preclinical human safety with information from post marketing.
  • 7. Phv methodologies  7 Phv historically relied on biological experiments or manual review of case report In vitro Safety Pharmacology Profiling (SPP) is one of the fundamental method for preclinical; by testing compounds with biochemical and cellular assays. SPP still not efficient (cost and time) Abdelfattah Al Zaqqa, PSUT-Amman-Jordan
  • 8. Computational methodologies for PhV  Vast quantities and complexity of data to be analyzed  Computational methods at both premarketing and post-marketing stages are more efficient in time and cost (i.e. can accurately detect ADRs in a timely fashion)  SPP still not efficient (cost and time) Abdelfattah Al Zaqqa, PSUT-Amman-Jordan 8  Datasets are available  EMA and NCA are example of specialized companies that maintain and develop database of ADRs
  • 9. What is Data mining ?!  Data mining  the process of extracting previously unknown, valid and actionable information from large information sources or databases  So what we will need to do this process?!  project goals: detection and prevention of ADRs  dataset acquisition: Available  data cleaning and preprocessing: organize the raw data obtained  data mining: extract useful information  data interpretation: Analysis of data  utilization: the act of using Abdelfattah Al Zaqqa, PSUT-Amman-Jordan 9
  • 10. Computational methodology-Pre-Marketing  Most of existing research devoted to develop computational methods.  These research can be categorized into I. protein target-based. II. chemical structure-based approaches. III. integrative approach. Abdelfattah Al Zaqqa, PSUT-Amman-Jordan 10
  • 11. Computational methodology-Pre-Marketing-Protein target-based  Drugs typically work by activating or inhibiting the function of a protein, which in turn results in therapeutic benefits to a patient.  drugs with similar in vitro protein binding profiles tend to similar side-effects, Fliri et al.  Fukuzaki et al, proposed a method to predict ADRs using subpathways “cooperative pathways” (pathways that function together).  They developed an algorithm called CoopeRativE Pathway Enumerator (CREPE) to select combinations of sub-pathways  it depends on the availability of gene-expression data observed under identical conditions. Abdelfattah Al Zaqqa, PSUT-Amman-Jordan 11
  • 12. CoopeRativE Pathway Enumerator (CREPE) V vertex, I itemset (activation conditions) Abdelfattah Al Zaqqa, PSUT-Amman-Jordan 12
  • 13. Computational methodology-PreMarketing-Protein target-based  More recently, Brouwers et al proposed that the side effect similarity of drugs could be attributed to their target proteins being close in a molecular network.  They proposed a pathway neighborhood measure to assess the closest distance of drug pairs according to their target proteins in the human protein protein interaction network and found network neighborhoods to only account for 5.8% of the side-effect similarities compared to 64% by shared drug targets. Abdelfattah Al Zaqqa, PSUT-Amman-Jordan 13
  • 14. Computational methodology-PreMarketing-Protein target-based  Pouliot et al. applied logistic regression (LR) models.  To identify potential ADRs manifesting in 19 specific system organ classes (SOCs), as defined by the Medical Dictionary for Regulatory Activities ,across 485 compounds in 508 BioAssays in the PubChem database.  The models were evaluated using leave-one-out-crossvalidation. The mean AUCs (area under the receiver operating characteristic curve) ranged from 0.60 to 0.92 across different SOCs. Abdelfattah Al Zaqqa, PSUT-Amman-Jordan 14
  • 15. Chemical Structure-based Approachpremarketing  It attempts to link ADRs to their chemical structure.  Bender et al, explore the correlation but the positive predictive was quit low under 0.5. but at least he proved the concept.  Hammann et al, employed decision tree to determine the chemical, physical, and structural properties of compounds that predispose them to causing ADRs  Hammann focused on ADRs in centerla nervous system (CNS),liver, and kidney.  Hammann decision tree model positive predictive accuracies ranging from 78.9% to 90.2%. Abdelfattah Al Zaqqa, PSUT-Amman-Jordan 15
  • 16. Chemical Structure-based Approachpremarketing  Pauwels et al. developed a sparse canonical correlation analysis (SCCA) method to predict high-dimensional side-effect profiles of drug molecules based on the chemical structures.  They predict 1385 side effects in the SIDER DB from chemical structures of 888 approved drugs.  16 Pauwels et al best resulting AUC(area under curve) was between 0.6088 and 0.8932 • SCCA examines the relationships of many variables of different types simultaneously Abdelfattah Al Zaqqa, PSUT-Amman-Jordan
  • 17. Integrative Approach- premarketing  Huang et al. proposed a new computational framework to predict ADRs by integrating systems biology data that include protein targets, proteinprotein interaction network, gene ontology (GO) annotation ,and reported side effects. They predict heart-related ADRs (i.e. cardio toxicity), which resulted in the highest AUC of 0.771.  Recently, Liu et al. investigated the use of phenotypic information, together with chemical and biological properties of drugs, to predict ADRs. using five machine learning algorithms: LR, Naïve Bayes (NB), KNearest Neighbor (KNN), Random Forest (RF), and SVM. Abdelfattah Al Zaqqa, PSUT-Amman-Jordan 17
  • 18. Integrative Approach  integration of chemical, biological, and phenotypic properties outperforms the chemical structured-based method (from 0.9054 to 0.9524 with SVM) and has the potential to detect clinically important ADRs at both preclinical and post-market phases for drug surveillance. Abdelfattah Al Zaqqa, PSUT-Amman-Jordan 18
  • 19. Post Marketing  many ADRs may still be missed because the clinical trials are often small, short, and biased by excluding patients with comorbid diseases.  do not mirror actual clinical use situations for diverse populations   (e.g. inpatient) thus it is important to continue the surveillance postmarket. Abdelfattah Al Zaqqa, PSUT-Amman-Jordan 19
  • 20. Computational methodology-Post marketing-Data sources  Spontaneous reporting systems (SRSs) is the core data-collection system for postmarketing drug surveillance since 1960. US FDA and the VigiBase maintain such as these report.  World Health Organization (WHO) manage these SRSs. Abdelfattah Al Zaqqa, PSUT-Amman-Jordan 20
  • 21. Post marketing-Spontaneous Reports  Disproportionality Analysis (DPA) involves frequency analyses of 2x2 contingency tables to quantify the degree to which a drug and ADR cooccurs “disproportionally” compared with what would be expected if there were no association ADR No ADR Total Drug a b N=a+b No Drug c d c+d Total M=a+c B+d T=a+b+c+d Abdelfattah Al Zaqqa, PSUT-Amman-Jordan 21
  • 22. Post marketing-Spontaneous Reports  Many approaches are applied the straightforward method is the calculation of frequentist metrics Association Measures Definition Relative Reporting Ratio (RRR) (t * a) / (m * n) Proportional Reporting Ratio (PRR) (a * (t – n)) / (c * n) Reporting Odds Ratio (ROR) (a * d) / (c * b) • Definitions of the frequentist measures of association Abdelfattah Al Zaqqa, PSUT-Amman-Jordan 22
  • 23. Post marketing-Spontaneous Reports  Other algorithms were also developed but they are more complex, such as gamma-Poisson shrinker (GPS) and the multi-item gamma-Poisson shrinker (MGPS)  DPA methods are effective in detecting single Drug-ADR associations Abdelfattah Al Zaqqa, PSUT-Amman-Jordan 23
  • 24. Data Mining Algorithms  DPA methods are effective in detecting single Drug-ADR associations  Data mining for multi-item ADR associations.  Harpaz et al identified 1167 multi-item ADR associations Using a set of 162,744 reports submitted to the FDA in 2008, 67% were validated by a domain expert  Tatonetti et al applied the bi clustering algorithm to identify drug groups that share a common set of ADRs in SRS data.  They discovered ADRs between drugs that couldn’t be discovered using DPA method.(e.g pravastatin and paroxetine had effect on blood glucose) Abdelfattah Al Zaqqa, PSUT-Amman-Jordan 24
  • 25. Post marketing -Electronic Medical Records  Electronic Medical Records :is a computerized medical record created in an organization that delivers care, EMRs contain not only detailed patient information but also copious longitudinal clinical data.  EMR databases consist of data in two types formats: (1) structured (e.g., laboratory data)  Several groups have employed computational methods on structured or coded data in EMRs to identify specific ADR signals (2) unstructured (narrative clinical notes). Abdelfattah Al Zaqqa, PSUT-Amman-Jordan 25
  • 26. Structured & unstructured Abdelfattah Al Zaqqa, PSUT-Amman-Jordan 26
  • 27. Post marketing -Electronic Medical Records-structured data  Yoon et al, demonstrated laboratory abnormality to be a valuable source for PhV by examining the odds ratio of laboratory abnormalities between a drug-exposed and a matched unexposed group using 10 years of EMR data.  Evaluation of their algorithm on 470 randomly selected drug-andabnormal-lab-event pairs produced a positive predictive value of 0.837 and negative predictive value of 0.659. Abdelfattah Al Zaqqa, PSUT-Amman-Jordan 27
  • 28. Post marketing -Electronic Medical Records-Unstructured Data  natural language processing (NLP) technique is required to extract the needed information from unstructured data.  Wang et al first employed NLP techniques to extract drug-ADR  Link Abdelfattah Al Zaqqa, PSUT-Amman-Jordan 28
  • 29. Non-conventional Data Sources-Post marketing 1. Biomedical Literature  Shetty and Dalal retrieved articles (published between 1949 and2009), for prioritizing drug-ADR associations.  DPA was applied to identify statistically significant pairs from the thousands of pairs in the remaining articles.  Evaluation showed that the method identified true associations with 0.41 and 0.71 inprecision and recall, respectively. Abdelfattah Al Zaqqa, PSUT-Amman-Jordan 29
  • 30. Non-conventional Data Sources 2. Health Forums  Data posted by users on health-related websites may also contain valuable drug safety information  mine drug-and-ADR from health –related websites (e.g. DailyStrength (http://www.dailystrength.org/))  System evaluation was conducted on a manually annotated set of 3600 user posts corresponding to 6 drugs. The system was shown to achieve 0.78 in precision and 0.70 in recall. Abdelfattah Al Zaqqa, PSUT-Amman-Jordan 30
  • 31. Non-conventional Data Sources  Chee et al, aggregated individuals’ opinions and review of drugs and used NLP technique to group drugs.  Some drugs were withdrawn from based on these messages. Abdelfattah Al Zaqqa, PSUT-Amman-Jordan 31
  • 32. 32 Future perspectives   This presentation provides a general overview of the current computational methodologies applied for PhV. basic concepts and highlight some representative work it is desirable to incorporate various data sources into one framework to understand ADRs. Abdelfattah Al Zaqqa, PSUT-Amman-Jordan  Data mining algorithms are applicable and useful to detect drugs interactions.  EMR for ADR prediction is not readily accessible for data mining, more sophisticated studies and NLP techniques is needed.  cause-and-effect relationships is an intrinsically hard problem in data mining and need to be further investigated for the PhV application.
  • 34. References  Oxford English Dictionary definition of "medicine“  Source: The Importance of Pharmacovigilance, WHO 2002  Budnitz, D.S., Pollock, D.A., Weidenbach, K.N.,Mendelsohn, A.B., Schroeder, T.J. and Annest, J.L. National surveillance of emergency department visits for outpatient adverse drug events. JAMA, 296, 15 (Oct 18 2006), 1858-1866.  Hopkins, A.L. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol, 4, 11 (Nov 2008), 682-690.  Helma C, Gottmann E, Kramer S. Knowledge discovery and data mining in toxicology. Stat Meth Med Res. 2000;9:329–58.  http://articles.mercola.com/sites/articles/archive/2012/02/11/leading-causesof-death-cost-for-us-economy.aspx  Mutsumi Fukuzaki, Mio Seki,Side Effect Prediction using Cooperative Pathways Abdelfattah Al Zaqqa, PSUT-Amman-Jordan 34
  • 35. Thank you! Abdelfattah Al Zaqqa, PSUT-Amman-Jordan 35

Hinweis der Redaktion

  1. Thehypothesis is that if a compound binds to a certain target, then itseffect may translate into possible occurrence of an ADR inhumans.
  2. coadministrationof pravastatin and paroxetine had a synergisticeffect on blood glucose.